Effect of radioiodine therapy on pulmonary alveolar-capillary membrane integrity.
The effects of large doses of radioiodine on the pulmonary alveolar-capillary membrane using 99mTc-DTPA clearance as an index of pulmonary damage in subjects with pulmonary metastases of differentiated thyroid carcinoma were studied.


METHODS
Technetium-99m-DTPA radioaerosols were generated by a dry aerosol generator. Data were acquired and analyzed for clearance half-time from the lungs with a scintillation camera. The study was carried out on 35 thyroid cancer patients with pulmonary metastases and on 32 patients without metastases; the results were compared to those of a control group comprising 52 subjects. The radiation dose delivered to the lungs from the therapeutic dose was calculated using MIRD methodology.


RESULTS
Cumulative radioiodine doses varied from 5.9 to 44.2 GBq (158-1194 mCi). The half-time clearance of 99mTc-DTPA was comparable in both patient groups and was not related to the total administered radioiodine dosage or to the radiation dose delivered to the lungs. No changes were observed for periods up to 5 yr after receiving the last radioiodine dosage. Seven patients followed at regular intervals from 6 mo to 2 yr did not show abnormal 99mTc-DTPA clearance values. One patient did show low 99mTc-DTPA clearance half-time values, which were symptomatic radiation pneumonitis. She had received a total dose of 34 GBq (922 mCi) over a 4-yr period.


CONCLUSIONS
The incidence of pulmonary damage resulting from radioiodine therapy for lung metastases of differentiated thyroid cancer is negligible, as evidenced by the normal pulmonary clearance half-time of 99mTc-DTPA aerosols.
Samuel
A M
AM
Radiation Medicine Centre, Bhabha Atomic Research Centre, Parel, Bombay.
Unnikrishnan
T P
TP
Baghel
N S
NS
Rajashekharrao
B
B
D000328:Adult; D000336:Aerosols; D000368:Aged; D002196:Capillaries / Q000528:radiation effects; D005260:Female; D006207:Half-Life; D006801:Humans; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D008168:Lung / Q000000981:diagnostic imaging; D008171:Lung Diseases / Q000000981:diagnostic imaging / Q000209:etiology; D008175:Lung Neoplasms / Q000503:physiopathology / Q000556:secondary; D008297:Male; D008875:Middle Aged; D008961:Models, Structural; D011650:Pulmonary Alveoli / Q000098:blood supply* / Q000528:radiation effects*; D011832:Radiation Injuries / Q000000981:diagnostic imaging; D011877:Radionuclide Imaging; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D015656:Respiratory Mechanics / Q000528:radiation effects; D016284:Technetium Tc 99m Pentetate / Q000008:administration & dosage; D013964:Thyroid Neoplasms / Q000473:pathology / Q000532:radiotherapy
D000336:Aerosols; D007457:Iodine Radioisotopes; D016284:Technetium Tc 99m Pentetate